Cargando…
Fingolimod impairs inactivated vaccine (CoronaVac)-induced antibody response to SARS-CoV-2 spike protein in persons with multiple sclerosis
BACKGROUND: : The impact of disease-modifying treatments on humoral response induced by inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines is understudied. METHODS: : We recruited 34 persons with multiple sclerosis (MS) under fingolimod treatment and 25 healthy individ...
Autores principales: | Türkoğlu, Recai, Baliç, Nesrin, Kızılay, Tuğçe, Erol, Ruziye, Akbayır, Ece, Yılmaz, Vuslat, Tüzün, Erdem |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8747775/ https://www.ncbi.nlm.nih.gov/pubmed/35033838 http://dx.doi.org/10.1016/j.msard.2022.103524 |
Ejemplares similares
-
Phosphorylated Neurofilament Heavy Chain (pNFH) in Clinically Isolated Syndrome and Multiple Sclerosis
por: TÜZÜN, Erdem, et al.
Publicado: (2021) -
Boosting immunity after CoronaVac
por: Sester, Martina, et al.
Publicado: (2022) -
Minimal change disease following vaccination with CoronaVac
por: Dirim, Ahmet Burak, et al.
Publicado: (2021) -
Immunogenicity of Mix-and-Match CoronaVac/BNT162b2 Regimen versus Homologous CoronaVac/CoronaVac Vaccination: A Single-Blinded, Randomized, Parallel Group Superiority Trial
por: Samoud, Samar, et al.
Publicado: (2023) -
CoronaVac efficacy data from Turkey
por: McMenamin, Martina E, et al.
Publicado: (2021)